Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-20-000024
Filing Date
2020-08-06
Accepted
2020-08-06 07:01:25
Documents
75
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20200630.htm   iXBRL 10-Q 1596275
2 EX-31.1 vndaex311630202010q.htm EX-31.1 13252
3 EX-31.2 vndaex312630202010q.htm EX-31.2 12852
4 EX-32.1 vndaex321630202010q.htm EX-32.1 9300
  Complete submission text file 0001347178-20-000024.txt   6502911

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20200630.xsd EX-101.SCH 45397
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20200630_cal.xml EX-101.CAL 81403
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20200630_def.xml EX-101.DEF 198885
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20200630_lab.xml EX-101.LAB 508655
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20200630_pre.xml EX-101.PRE 343961
10 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20200630_htm.xml XML 1133538
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 201079736
SIC: 2834 Pharmaceutical Preparations